LianBio (LIANY)

Market Cap	9.84M -67.5%
Revenue (ttm)	n/a
Net Income	-87.98M
EPS	-0.82
Shares Out	108.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.38 (417.58%)
Ex-Dividend Date	Jul 15, 2025

Volume	n/a
Average Volume	109,160
Open	0.0910
Previous Close	0.0910
Day's Range	0.0910 - 0.0910
52-Week Range	0.0300 - 0.4394
Beta	0.42
RSI	49.80
Earnings Date	n/a

About LianBio

LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 163
• Stock Exchange: OTCMKTS
• Ticker Symbol: LIANY